The Urgent Need: Key Cardiology Statistics

17.9M

Cardiovascular diseases are the leading cause of death globally, responsible for 17.9 million deaths per year (WHO)1

64M+

Number of people living with heart failure globally2

40-50%

Heart Failure with Preserved Ejection Fraction (HFpEF)3 affects 40-50% of heart failure patients, with a 1-year all-cause mortality rate of 23% in HFpEF patients4

13%

Up to 13% of HFpEF patients may have undiagnosed amyloidosis5

Looking to the Future

The prevalence of heart failure is increasing, driven by aging populations, higher survival rates from acute cardiovascular events (e.g., MI), and rising rates of diabetes, hypertension, and obesity. Heart failure is a leading cause of hospitalization in people over age 65.
 
eMyosound was founded to address the clinical gap in HFpEF diagnosis by leveraging the biomarker for myocardial stiffness to change the course of heart failure diagnosis and improve patient outcomes.

Clinical development: A Timeline

2025

Boston Clinical Benchmark Study

A multi-centric clinical benchmark study including Massachusetts General Hospital, Brigham and Women’s Hospital, and Boston Medical Center.

2024-2025

Amyloscan Study

Study at Mondor’s Hospital with Prof. T. Damy, further exploring key applications.

2018

First Clinical Proof of Concept

First clinical proof of concept conducted at the European Hospital Georges Pompidou on 80 adults, successfully validating the technology on humans and establishing normal stiffness values based on age. Additional pediatric tests were conducted at Necker Hospital.

2011-2017

Preclinical Validation

Preclinical validation on tissue samples and animal models demonstrating the feasibility of the technology for cardiac stiffness measurements.

2009-2015

PhysMed Studies

Development of advanced technology concepts for cardiac stiffness measurement using ultrasound imaging. Multiple challenges were addressed, resulting in laboratory prototypes.

timeline pattern

Scientific Advisory Board 

Emmanuel Messas, MD, PhD

Professor of Cardiology and Vascular Diseases at Hôpital Européen Georges Pompidou — AP-HP and Université Paris Cité. Director of the Cardiovascular Prevention Department and expert in echocardiography. Scientific Advisory board Coordinator at DMU Cardio-Vascular and Transplantation — HYPERVASC. Co-inventor of Valvosoft (Cardiawave), an ultrasound-based therapy for valvular heart disease, contributing to the development of innovative non-invasive treatments.

Thibaud Damy, MD, PhD

Professor of Cardiology and Vascular Diseases at Henri Mondor Hospital, Paris. International leader in heart failure and cardiac amyloidosis. Director of the Referral Center for Cardiac Amyloidosis in France, overseeing patient care and research. Leads educational initiatives such as Amylo-PEP and coordinates the European Amyloidosis Registry.

Frederick L. Ruberg, MD

Thomas J. Ryan Professor and Chief of Cardiovascular Medicine at Boston University. Professor of Radiology and Director of Workforce Development at the Boston University Clinical and Translational Science Institute. Senior Associate Editor for Circulation: Cardiovascular Imaging and a principal investigator in amyloidosis research, notably the ATTR-ACT tafamidis RCT and SCAN-MP screening trial.

Mathew S. Maurer, MD

Professor of Medicine at Columbia University Irving Medical Center, specializing in advanced heart failure, transplant cardiology, and cardiovascular disease. A leading researcher in cardiac amyloidosis, involved in major clinical studies, including the ATTR-ACT tafamidis RCT and SCAN-MP screening trial.

Robert A. Levine, MD

Senior physician in the Cardiac Ultrasound Laboratory at Massachusetts General Hospital. Internationally recognized expert in cardiac imaging and valvular heart disease. Leads the Leducq MITRAL Transatlantic Network, facilitating collaborations between basic science and clinical research to advance innovative therapies for valvular disease.

Albert Hagège, MD, PhD

Professor of Cardiology and Vascular Diseases at Hôpital Européen Georges Pompidou. Renowned expert in cardiac imaging and heart failure, with more than 150 publications in peer-reviewed journals. Fellow of the European Society of Cardiology and former President of the French Society of Cardiology.

Sanjiv J. Shah, MD

Stone Endowed Professor of Medicine at Northwestern University Feinberg School of Medicine. Director of Research at Bluhm Cardiovascular Institute and Director of the Northwestern HFpEF Program. Recognized for his expertise in heart failure with preserved ejection fraction (HFpEF) and precision medicine, contributing significantly to advancing cardiovascular research and treatment strategies.

Prof. Mickaël Tanter

Professor (INSERM), Member of the French Academy of Science

  • Recognized as a world leader in ultrasound biotechnologies
  • Co-inventor of Fibroscan (Echosens), Aixplorer (SuperSonic Imagine), Valvosoft (Cardiawave), and Iconeus One (Iconeus) technologies

Mathieu Pernot, PhD

Physicist, Research Director (INSERM), Director of Physics for Medicine Paris Institute (INSERM, CNRS, ESPCI-Paris PSL)

  • Recognized as a leading expert in biomedical ultrasound

Clément Papadacci, PhD

Physicist, Researcher (INSERM and Physics for Medicine Paris Institute)

  • Specializes in ultrasound elastography for cardiac applications

References

Background pattern topBackground pattern bottom

Let’s Connect

Whether you’re a clinician, researcher, or industry leader, we invite you to join eMyosound’s mission in transforming cardiac healthcare for patients.

Contact Us